Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Efficacy after Transition to SB5 from Reference Adalimumab (Humira (R)) Vs. Continuation of SB5 or Reference Adalimumab By Antibodies Developed after Transition from a SB5 Phase III Study Genovese, M. C., Weinblatt, M., Keystone, E. C., Baranauskaite, A., Cheong, S., Ghil, J. WILEY. 2016
View details for Web of Science ID 000417143401028